Drug Name: Kimmtrak
Indications: To treat unresectable or metastatic uveal melanoma.
Active Ingredient: Tebentafusp-tebn
Company: Immunocore Commercial LLC
Approval Date: 1/25/2022
More Details: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kimmtrak